A pilot study of topical treatment with an α2-agonist in patients with retinal dystrophies

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 1, 2008, Pages 80-86

  Merin, Saul ^a   Obolensky, Alexey ^a   Farber, Marilyn D ^a   Chowers, Itay ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ARTIFICIAL TEAR; BRIMONIDINE; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLOR VISION TEST; CONTRAST SENSITIVITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; ELECTRORETINOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; NEUROPROTECTION; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA DYSTROPHY; RETINITIS PIGMENTOSA; VISUAL ACUITY; VISUAL FIELD; VISUAL FIELD DEFECT;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ADULT; AGED; CONTRAST SENSITIVITY; ELECTRORETINOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PILOT PROJECTS; PROSPECTIVE STUDIES; QUINOXALINES; RECEPTORS, ADRENERGIC, ALPHA-2; RETINAL DEGENERATION; RETINAL DISEASES; RETINITIS PIGMENTOSA; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELDS;

EID: 38549085164     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0022     Document Type: Article

References (32)

1. van Soest, S., Westerveld, A., de Jong, P.T., et al. Retinitis pigmentosa: Defined from a molecular point of view. Surv. Ophthalmol. 43:321-334, 1999.
2. Bishara, S., Merin, S., Cooper, M., et al. Combined vitamin A and E therapy prevents retinal electrophysiological deterioration in abetalipoproteinaemia. Br. J. Ophthalmol. 66:767-770, 1982.
3. Berson, E.L., Rosner, B., Sandberg, M.A., et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch. Ophthalmol. 111:761-772, 1993.
4. Fishman, G.A., Gilbert, L.D., Fiscella, R.G., et al. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch. Ophthalmol. 107:1445-1452, 1989.
5. Wenzel, A., Grimm, C., Samardzija, M., et al. Molecular mechanisms of light-induced photoreceptor apoptosis and neuroprotection for retinal degeneration. Prog. Retin. Eye Res. 24:275-306, 2005.
6. Ma, D., Rajakumaraswamy, N., and Maze, M. alpha2-adrenoceptor agonists: Shedding light on neuroprotection? Br. Med. Bull. 71:77-92, 2004.
7. Gao, H., Qiao, X., Cantor, L.B., et al. Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch. Ophthalmol. 120:797-803, 2002.
8. Acheampong, A.A., Shackleton, M., and Tang-Liu, D.D. Comparative ocular pharmacokinetics of brimonidine after a single-dose application to the eyes of albino and pigmented rabbits. Drug Metab. Dispos. 23:708-712, 1995.
9. Acheampong, A.A., Shackleton, M., John, B., et al. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug. Metab. Dispos. 30:421-429, 2002.
10. Kent, A.R., Nussdorf, J.D., David, R., et al. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology 108:784-787, 2001.
11. Wheeler, L.A., and Woldemussie, E. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma. Eur. J. Ophthalmol. 11(Suppl. 2):S30-S35, 2001.
12. Wheeler, L.A., Gil, D.W., and WoldeMussie, E. Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv. Ophthalmol. 2001;45(Suppl. 3):S290-S294; discussion S5-S6.
13. Maier, C., Steinberg, G.K., Sun, G.H., et al. Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 79:306-312, 1993.
14. Burke, J., and Schwartz, M. Preclinical evaluation of brimonidine. Surv. Ophthalmol. 41(Suppl. 1):S9-S18, 1996.
15. WoldeMussie, E., Ruiz, G., Wijono, M., et al. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest. Ophthalmol. Vis. Sci. 42:2849-2855, 2001.
16. Wheeler, L., WoldeMussie, E., and Lai, R. Role of alpha-2 agonists in neuroprotection. Surv. Ophthalmol. 48(Suppl. 1):S47-S51, 2003.
17. Levkovitch-Verbin, H., Harris-Cerruti, C., Groner, Y., et al. RGC death in mice after optic nerve crush injury: Oxidative stress and neuroprotection. Invest. Ophthalmol. Vis. Sci. 41:4169-4174, 2000.
18. Lafuente, M.P., Villegas-Perez, M.P., Sobrado-Calvo, P., et al. Neuroprotective effects of alpha(2)-selective adrenergic agonists against ischemia-induced retinal ganglion cell death. Invest. Ophthalmol. Vis. Sci. 42:2074-2084, 2001.
19. Donello, J.E., Padillo, E.U., Webster, M.L., et al. alpha(2)-adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J. Pharmacol. Exp. Ther. 296:216-223, 2001.
20. Wen, R., Cheng, T., Li, Y., et al. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J. Neurosci. 16:5986-5992, 1996.
21. Dandekar, S.S., Ebenezer, N.D., Grayson, C., et al. An atypical phenotype of macular and peripapillary retinal atrophy caused by a mutation in the RP2 gene. Br. J. Ophthalmol. 88:528-532, 2004.
22. Janaky, M., Palffy, A., Deak, A., et al. Multifocal ERG reveals several patterns of cone degeneration in retinitis pigmentosa with concentric narrowing of the visual field. Invest. Ophthalmol. Vis. Sci. 48:383-389, 2007.
23. Barsam, A., and Laidlaw, A. Visual fields in patients who have undergone vitrectomy for complications of diabetic retinopathy. A prospective study. BMC Ophthalmol. 6:5, 2006.
24. Aviles-Trigueros, M., Mayor-Torroglosa, S., Garcia-Aviles, A., et al. Transient ischemia of the retina results in massive degeneration of the retinotectal projection: long-term neuroprotection with brimonidine. Exp. Neurol. 184:767-777, 2003.
25. Mayor-Torroglosa, S., De la Villa, P., Rodriguez, M.E., et al. Ischemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: neuroprotection with brimonidine. Invest. Ophthalmol. Vis. Sci. 46:3825-3835, 2005.
26. Danylkova, N.O., Alcala, S.R., Pomeranz, H.D., et al. Neuroprotective effects of brimonidine treatment in a rodent model of ischemic optic neuropathy. Exp. Eye Res. 84:293-301, 2007.
27. Ferencz, J.R., Gilady, G., Harel, O., et al. Topical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularization. Graefe's Arch. Clin. Exp. Ophthalmol. 243:877-880, 2005.
28. Evans, D.W., Hosking, S.L., Gherghel, D., et al. Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: A case for neuroprotection. Br. J. Ophthalmol. 87:1463-1465, 2003.
29. Wilhelm, B., Ludtke, H., and Wilhelm, H. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): A 3-month, double-masked, randomised, placebo-controlled trial. Graefe's Arch. Clin. Exp. Ophthalmol. 244:551-558, 2006.
30. Bowman, R.J., Cope, J., and Nischal, K.K. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye 18:24-26, 2004.
31. Al-Shahwan, S., Al-Torbak, A.A., Turkmani, S., et al. Side-effect profile of brimonidine tartrate in children. Ophthalmology 112:21-43, 2005.
32. Piltz, J., Gross, R., Shin, D.H., et al. Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study. Am. J. Ophthalmol. 130:441-453, 2000.